Logo do repositório
 
Publicação

Novel particulate BCG-loaded delivery system for mucosal immunization against tuberculosis

datacite.subject.fosCiências Médicas::Medicina Básicapt_PT
dc.contributor.advisorGonçalves, Lídia Maria Diogo
dc.contributor.advisorAlmeida, António José Leitão das Neves, 1963-
dc.contributor.authorCaetano, Liliana Aranha
dc.date.accessioned2016-06-08T15:28:05Z
dc.date.available2016-06-08T15:28:05Z
dc.date.issued2016
dc.date.submitted2016
dc.descriptionTese de doutoramento, Farmácia (Tecnologia Farmacêutica), Universidade de Lisboa, Faculdade de Farmácia, 2016pt_PT
dc.description.abstractIt has been well described that mucosal immune responses are of major important for protection against pathogens invading the organism via mucosal surfaces, such as Mycobacterium tuberculosis. Current vaccine against tuberculosis, attenuated Mycobacterium bovis bacilli Calmette-Guérin (BCG), is commonly regarded as unsatisfactory due to its limited protection in adults against tuberculosis. The recognition that physicochemical properties, and route of administration, of vaccines influence their bioavailability and immunogenicity has led to intense research in the field of vaccine delivery. Several strategies can be employed in order to increase the immunogenicity of vaccines, namely by associating the antigens with suitable carriers and by choosing alternative vaccination routes. The aim of this thesis was to investigate the biocompatibility, cellular interaction, and immunogenicity of different types of surface modified BCG, such as BCG-loaded chitosan-alginate microparticles and BCG associated with chitosan. Polymeric nano-/microparticles have emerged as promising vaccine carriers for mucosal immunization due to their ability to improve mucoadhesion and delivery of antigens to the mucosa, while acting as adjuvants. In this context, BCG was encapsulated into polymeric microparticles composed by chitosan, chitosan and alginate, or chitosan and alginate containing linoleic acid. All particles were prepared using an optimized ionic gelation method, presenting a spherical morphology within the micrometre size range, high drug encapsulation and yield of preparation. The addition of chitosan to BCG was found to reverse its surface charge, without compromising cell viability. Studies conducted on THP-1 cells have shown that, although some formulations induced a slight decrease in cell viability, all of them were considered biocompatible. In addition, the BCG-loaded microparticles were found to be quickly internalized by human macrophages. These results highlight the potential of BCG-loaded microparticles for whole live bacterial vaccine encapsulation. Two independent in vivo experiments with BALB/c mice showed that the association of BCG with polymeric microparticles or chitosan endowed the vaccine with predominant Th1 type immunogenicity following intranasal vaccination, whereas the association of BCG with polymeric microparticles containing linoleic acid enabled a balanced Th1/Th2 profile, with a specific IgG2a/IgG1 ratio around the unity. The BCG-loaded polymeric microparticles containing linoleic acid were also found to increase the production of Th1 type cytokines, namely TNF-α, IL-2 and IFN-γ, and to promote the secretion of specific IgA in the lung. These results constituted the first quantitative analysis of the immune responses elicited in mice by BCG-loaded chitosan-alginate microparticles containing linoleic acid administered by intranasal route, highlighting the potential of this carrier in improving cellular and mucosal immune responses as pre-exposure vaccine for tuberculosis. In conclusion, polymeric microparticles proved to be a versatile platform for the delivery of attenuated vaccines, with high biocompatibility and easy surface modification, thus making them potential candidates as mucosal vaccine delivery systems. The results of this study also provide information on the adjuvant effects of the innovative association of BCG with polymeric microparticles, leading to the enhancement of cellular and mucosal immune responses following intranasal immunization, as well as on their interaction with macrophages.pt_PT
dc.description.provenanceSubmitted by Amelia Janeiro (ajaneiro@reitoria.ul.pt) on 2016-06-01T14:52:09Z No. of bitstreams: 1 ulsd072849_td_Liliana_Caetano.pdf: 2780401 bytes, checksum: f15755902a542be6fa9e3008c1df2fd6 (MD5)en
dc.description.provenanceMade available in DSpace on 2016-06-08T15:28:05Z (GMT). No. of bitstreams: 1 ulsd072849_td_Liliana_Caetano.pdf: 2780401 bytes, checksum: f15755902a542be6fa9e3008c1df2fd6 (MD5) Previous issue date: 2016en
dc.description.sponsorshipPrémio Caixa Geral de Depósitos - ESTeSLIPL/CGD/2012; Fundação para a Ciência e a Tecnologia (FCT), projeto PEst-OE/SAU/UI4013/2011pt_PT
dc.identifier.tid101412649
dc.identifier.urihttp://hdl.handle.net/10451/24003
dc.language.isoengpt_PT
dc.subjectTeses de doutoramento - 2016pt_PT
dc.titleNovel particulate BCG-loaded delivery system for mucosal immunization against tuberculosispt_PT
dc.typedoctoral thesis
dspace.entity.typePublication
person.familyNameCaetano
person.givenNameLiliana Aranha
person.identifier166296
person.identifier.ciencia-id9716-9DAC-532A
person.identifier.orcid0000-0003-1496-2609
person.identifier.ridO-4292-2016
person.identifier.scopus-author-id55490838100
rcaap.rightsopenAccesspt_PT
rcaap.typedoctoralThesispt_PT
relation.isAuthorOfPublication928eb371-e67a-46b6-b261-3d68dca35754
relation.isAuthorOfPublication.latestForDiscovery928eb371-e67a-46b6-b261-3d68dca35754
thesis.degree.nameDoutoramento em Farmáciapt_PT

Ficheiros

Principais
A mostrar 1 - 1 de 1
A carregar...
Miniatura
Nome:
ulsd072849_td_Liliana_Caetano.pdf
Tamanho:
2.65 MB
Formato:
Adobe Portable Document Format
Licença
A mostrar 1 - 1 de 1
Miniatura indisponível
Nome:
license.txt
Tamanho:
1.2 KB
Formato:
Item-specific license agreed upon to submission
Descrição:

Coleções